Year-to-date money raised in public, private and other financings of biopharma companies.

Total raised in public, private and other financings of biopharma companies, comparing 2019-2024.

BioWorld's offices will be closed in observance of Good Friday. No issue will be published April 18.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bioarctic, Eisai, Innocare, Neurelis, Recordati.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bluebird, Cara, Elix, Geovax, Oncopeptides, Prism Biolab, Tvardi.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Belhaven, Briacell, Telix.

New hires and promotions in the biopharma industry, including: Addgene, Airna, Arrowhead, Concept, Conduit, Decoy, Madrigal, Neuronos, Organon, Phathom, Protara.

Biopharma deal value declined in the first three months of 2025 compared to the previous quarter, but remained above the 2024 quarterly average of $57.63 billion. In the first quarter (Q1), biopharma deals totaled $66.86 billion across 330 transactions, a decrease from $80.65 billion in Q4 2024, which saw 372 deals. However, this was a significant value increase from Q1 2024, when deals amounted to $44.32 billion across 376 transactions.